Gina Battaglia | Authors

October 30, 2020

The high variability in responses among different types of HRAS-altered cancers highlights the need to identify rational therapeutic combinations that enhance response to HRAS-directed therapies.

July 25, 2020

The efficacy of each combination therapy targeting KRAS will likely depend on the tumor lineage, said Gordon Mills, MD, PhD.

April 03, 2020

PARP inhibitors following platinum-based chemotherapy as well as immunotherapy combinations have shown early signs of efficacy in metastatic pancreatic cancer with homologous recombination deficiency, according to data presented at the 2020 Gastrointestinal Cancers Symposium, held January 23 to 25 in San Francisco, California.

October 06, 2016

Recent randomized clinical trials that have combined immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy for the treatment of patients with lung cancer have shown promising results for these combinations.

September 23, 2015

Frequency of the cell death-regulating protein Bim (BCL-2-interacting mediator of cell death) may predict patient response to PD-1 inhibitor immunotherapy.

August 28, 2015

Patients with epithelial ovarian cancer who took non-selective beta blockers (NSBBs) during chemotherapy had significantly improved overall survival (OS) than those who did not.